ABCD-Trial: study protocol for a randomized, double-blind, placebo-controlled study in patients with Amyotrophic lateral sclerosis for the evaluation of efficacy and safety of B-Cell Depletion with rituximab (ABCD). (PubMed, Trials) - Oct 22, 2026 - "ALS is a rapidly progressive neurodegenerative disease with limited treatment options. Recent preclinical in vivo studies suggest that B-cell-mediated autoimmunity contributes to disease progression. This trial will evaluate whether rituximab, which specifically depletes CD20+ B-cells, can slow ALS progression and provide insights into disease mechanisms."
Clinical • Clinical protocol • Journal • Amyotrophic Lateral Sclerosis • CNS Disorders • Inflammation • CD20
|
|
André Maier; Anna Gámez; Annika Spottke; Friederike Ufer; Harald Prüss; Nadja Kemmerling-de Coninck; Nikolaus Behr; Patrick Weydt; Pia Naumann; Rebecca Sterl; Robert Nemeth; Rosa Rössling; Tamara Schaprian; Thomas Meyer
|